Oncogene alterations in carcinomas of the uterine cervix: Overexpression of the epidermal growth factor receptor is associated with poor prognosis

Clinical Cancer Research

Volumn 5, Issue 3, 1999, Pages 577-586

  Kersemaekers, Anne Marie F ^a   Fleuren, Gert Jan ^a   Kenter, Gemma G ^a   Van Den Broek, Lambert J C M ^a   Uljee, Sandra M ^a   Hermans, Jo ^a   Van De Vijver, Marc J ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P53; VIRUS DNA;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; DISEASE ASSOCIATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; ONCOGENE; ONCOGENE C ERB; ONCOGENE C MYC; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR VOLUME; UTERINE CERVIX CARCINOMA; WART VIRUS;

ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; GENES, ERBB-2; GENES, MYC; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; MITOTIC INDEX; MUTATION; NEOPLASM STAGING; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PAPILLOMAVIRIDAE; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL NEOPLASMS;

EID: 0033042754     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Gullick, W. J., Marsden, J. J., Whittle, N., Ward, B., Bobrow, L., and Waterfield, M. D. Expression of epidermal growth factor receptors on human cervical, ovarian, and vulval carcinomas. Cancer Res., 46: 285-292, 1986.
2. Dam, V. P. A., Lowe, D. G., Watson, J. V., James, M., Chard, T., Hudson, C. N., and Shepherd, J. H. Multiparameter flow-cytometric quantitation of epidermal growth factor receptor and c-erbB-2 oncoprotein in normal and neoplastic tissues of the female genital tract. Gynecol. Oncol., 42: 256-264, 1991.
3. Kim, J. W., Kim, Y. T., Kim, D. K., Song, C. H., and Lee, J. W. Expression of epidermal growth factor receptor in carcinoma of the cervix. Gynecol. Oncol., 60: 283-287, 1996.
4. Kristensen, G. B., Holm, R., Abeler, V. M., and Trope, C. G. Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c-erbB-2 in early cervical squamous cell carcinoma. Cancer (Phila.), 78: 433-440, 1996.
5. Pfeifer, D., Stellwag, B., Pfeifer, A., Borlinghaus, P., Meier, W., and Scheidel, P. Clinical implications of the epidermal growth factor receptor in the squamous cell carcinoma of the uterine cervix. Gynecol. Oncol., 33: 146-150, 1989.
6. Scambia, G., Ferrandina, G., Distefano, M., D'Agostino, G., Benedetti Panici, P., and Mancuso, S. Epidermal growth factor receptor (EGFR) is not related to the prognosis of cervical cancer. Cancer Lett., 123: 135-139, 1998.
7. De Potter, C. R. The Neu oncogene: more than a prognostic indicator? Hum. Pathol., 25: 1264-1268, 1994.
8. Bacus, S. S., Zelnick, C. R., Plowman, G., and Yarden, Y. Expression of the c-erb-2 family of growth factor receptors and their ligands in breast cancer. Implication for tumor biology and clinical behavior. Am. J. Clin. Pathol., 102 (Suppl. 1): S13-S24, 1994.
9. Kihana, T., Tsuda, H., Teshima, S., Nomoto, K., Tsugane, S., Sonoda, T., Matsuura, S., and Hirohashi, S. Prognostic significance of the overexpression of c-erbB-2 protein in adenocarcinoma of the uterine cervix. Cancer (Phila.), 73: 148-153, 1994.
10. Mandai, M., Konishi, I., Koshiyama, M., Komatsu, T., Yamamoto, S., Nanbu, K., Mori, T., and Fukumoto, M. Altered expression of nm23-H1 and c-erbB-2 proteins have prognostic significance in adenocarcinoma but not in squamous cell carcinoma of the uterine cervix. Cancer (Phila.), 75: 2523-2529, 1995.
11. Costa, M. J., Walls, J., and Trelford, J. D. C-erbB-2 oncoprotein overexpression in uterine cervix carcinoma with glandular differentiation. Am. J. Clin. Pathol., 104: 634-642, 1995.
12. Oka, K., Nakano, T., and Arai, T. C-erbB-2 oncoprotein expression is associated with poor prognosis in squamous cell carcinoma of the cervix. Cancer (Phila.), 73: 668-671, 1994.
13. Hale, R. J., Buckley, C. H., Fox, H., and Williams, J. Prognostic value of c-erbB-2 expression in uterine cervical cancer. J. Clin. Pathol., 45: 594-596, 1992.
14. Greenblatt, M. S., Bennett, W. P., Hollstein, M., and Harris, C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54: 4855-4878, 1994.
15. Kim, J. W., Cho, Y. H., Lee, C. G., Kim, J. H., Kim, H. K., Kim, E. J., Han, K. T., and Namkoong, S. E. Human papillomavirus infection and TP53 gene mutation in primary cervical carcinoma. Acta Oncol., 36: 295-300, 1997.
16. Akasofu, M., and Oda, Y. Immunohistochemical detection of p53 in cervical epithelial lesions with or without infection of human papillomavirus types 16 and 18. Virchows Arch., 425: 593-602, 1995.
17. Milde-Langosch, K., Albrecht, K., Joram, S., Schlechte, H., Giessing, M., and Loning, T. Presence and persistence of HPV infection and p53 mutation in cancer of the cervix uteri and the vulva. Int. J. Cancer, 63: 639-645, 1995.
18. Miwa, K., Miyamoto, S., Kato, H., Imamura, T., Nishida, M., Yoshikawa, Y., Nagata, Y., and Wake, N. The role of p53 in human cervical cell carcinoma development. Br. J. Cancer, 71: 219-226, 1995.
19. Dellas, A., SchultHeiss, E., Almendral, A. C., Gudat, F., Oberholzer, M., Feichter, G., Moch, H., and Torhorst, J. Altered expression of mdm-2 and its association with p53 protein status, tumor-cell-proliferation rate and prognosis in cervical neoplasia. Int. J. Cancer. 74: 421-425, 1997.
20. Soini, Y., Mannermaa, A., Winqvist, R., Kamel, D., Poikonen, K., Kiviniemi, H., and Paakko, P. Application of fine-needle aspiration to the demonstration of ERBB2 and MYC expression by in situ hybridization in breast carcinoma. J. Histochem. Cytochem., 42: 795-803, 1994.
21. Leffak, M., and James, C. D. Opposite replication polarity of the germ line c-myc gene in HeLa cells compared with that of two Burkitt lymphoma cell lines. Mol. Cell. Biol., 9: 586-593, 1989.
22. Creasman, W. T. New gynecologic cancer staging (editorial). Gynecol. Oncol., 58: 157-158, 1995.
23. Vijver, M. J. v. d., Peterse, J. L., Mooi, W. J., Wisman, P., Lomans, J., Dalesio, O., and Nusse, R. Neu protein overexpression in breast cancer. N. Engl. J. Med., 319: 1239-1245, 1988.
24. Cattoretti, G., Pileri, S., Parravicini, C., Becker, M. H. G., Poggi, S., Bifulco, C., Key, G., D'Amato, L., Sabattini, E., Feudale, E., Reynolds, F., Gerdes, J., and Rilke, F. Antigen unmasking on formalin-fixed, paraffin-embedded tissue sections. J. Pathol., 171: 83-98, 1993.
25. Hazelbag, H. M., van den Broek, L. J. C. M., van Dorst, E. B. L., Offerhaus, G. J. A., Fleuren, G. J., and Hogendoorn, P. C. W. Immunostaining of chain-specific keratins on formalin-fixed, paraffin-embedded tissues: a comparison of various antigen retrieval systems using microwave heating and proteolytic pre-treatments. J. Histochem. Cytochem., 43: 429-437, 1995.
26. Devilee, P., Van den Broek, M., Kuipers-Dijkshoorn, N., Kolluri, R., Khan, P. M., Pearson, P. L., and Cornelisse, C. J. At least four different chromosomal regions are involved in loss of heterozygosity in human breast carcinoma. Genomics, 5: 554-560, 1989.
27. Bargmann, C. I., Hung, M. C., and Weinberg, R. A. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell, 45: 649-657, 1986.
28. Ullrich, A., Coussens, L., Hayflick, J. S., Dull, T. J., Gray, A., Tam, A. W., Lee, J., Yarden, Y., Libermann, T. A., Schlessinger, J., Downward, J., Mayes, E. L. V., Whittle, N., Waterfield, M. D., and Seeburg, P. H. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature (Lond.), 309: 418-425, 1984.
29. Marchetti, A., Buttitta, F., Girlando, S., Dalla Palma, P., Pellegrini, S., Doglioni, C., Bevilacqua, G., and Barbaresch, M. mdm2 gene alterations and mdm2 protein expression in breast carcinomas. J. Pathol., 175: 31-38, 1995.
30. Dalla Favera, R., Gelmann, E. P., Martinotti, S., Franchini, G., Papas, T. S., Gallo, R. C., and Wong-Staal, F. Cloning and characterization of different human sequences related to the onc gene (v-myc) of avian myelocytomatosis virus (MC29). Proc. Natl. Acad. Sci. USA, 79: 6497-6501, 1982.
31. Cole, S. T., and Danos, O. Nucleotide sequence and comparative analysis of the human papillomavirus type 18 genome; phylogeny of papillomaviruses and repeated structure of the E6 and E7 gene products. J. Mol. Biol., 193: 599-608, 1987.
32. Kersemaekers, A. M. F., Hermans, J., Fleuren, G. J., and van de Vijver, M. J. Loss of heterozygosity for defined regions on chromosomes 3, 11 and 17 in carcinoma of the uterine cervix. Br. J. Cancer, 77: 192-200, 1998.
33. Tieben, L. M., Schegget, J. T., Minnaar, R. P., Bouwes Bavinck, J. N., Berkhout, R. J. M., Vermeer, B. J., Jebbink, M. F., and Smits, H. L. Detection of cutaneous and genital HPV types in clinical samples by PCR using consensus primers. J. Virol. Methods, 42: 265-280, 1993.
34. Greer, C. E., Peterson, S. L., Kiviat, N. B., and Manos, M. M. PCR amplification from paraffin-embedded tissues: effects of fixative and fixation time. Am. J. Clin. Pathol., 95: 117-124, 1991.
35. Roda-Husman, A. M., Walboomers, J. M. M., Van den Brule, A. J. C., Meijer, C. J. L. M., and Snijders, P. J. F. The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J. Gen. Virol., 76: 1057-1062, 1995.
36. Bauer, H. M., Greer, C. E., and Manos, M. M. Determination of genital human papillomavirus infection by consensus PCR amplification. In: C. S. Herrington and J. O. McGee (eds.), Diagnostic Molecular Pathology. A Practical Approach, pp. 131-152. Oxford: Oxford University Press, 1992.
37. Manos, M. M., Wright, D. K., Lewis, A. J., Broker, T. R., and Wolinski, S. M. The use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. In: M. Furth and M. Greaves (eds.), Molecular Diagnostics of Human Cancer: Cancer Cells, pp. 209-214. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989.
38. Auvinen, E., Crusius, K., Steuer, B., and Alonso, A. Human papillomavirus type 16 E5 protein (review). Int. J. Oncol., 11: 1297-1304, 1997.
39. Pim, D., Collins, M., and Banks, L. Human papillomavirus type 16 E5 gene stimulates the transforming activity of the epidermal growth factor receptor. Oncogene, 7: 27-32, 1992.
40. Crusius, K., Auvinen, E., and Alonso, A. Enhancement of EGF- and PMA-mediated MAP kinase activation in cells expressing the human papillomavirus type 16 E5 protein. Oncogene, 15: 1437-1444, 1997.
41. Vecchione, A., Cermele, C., Giovagnoli, M. R., Valli, C., Alimandi, M., Carico, E., Esposito, D. L., Mariani-Costantini, R., and French, D. p53 expression and genetic evidence for viral infection in intraepithelial neoplasia of the uterine cervix. Gynecol. Oncol., 55: 343-348, 1994.
42. Hunt, C. R., Hale, R. J., Buckley, C. H., and Hunt, J. p53 expression in carcinoma of the cervix. J. Clin. Pathol., 49: 971-974, 1996.
43. Kurvinen, K., Syrjanen, K., and Syrjanen, S. p53 and bcl-2 proteins as prognostic markers in human papillomavirus-associated cervical lesions. J. Clin. Oncol., 14: 2120-2130, 1996.
44. Jeffers, M. D., Richmond, J., Farquharson, M., and McNicol, A. M. p53 immunoreactivity in cervical intraepithelial neoplasia and non-neoplastic cervical squamous epithelium. J. Clin. Pathol., 47: 1073-1076, 1994.
45. Cavuslu, S., Goodlad, J., Hobbs, C., Connor, A. M., Shanti Raju, K., Best, J. M., and Cason, J. Relationship between human papillomavirus infection and overexpression of p53 protein in cervical carcinomas and lymphnode metastases. J. Med. Virol., 53: 111-117, 1997.
46. Choo, K. B., and Chong, K. Y. Absence of mutation in the p53 and the retinoblastoma susceptibility genes in primary cervical carcinomas. Virology, 193: 1042-1046, 1993.
47. Chen, J. D., Lin, J. Y., and Levine, A. J. Regulation of transcription functions of the p53 tumor suppressor by the MDM-2 oncogene. Mol. Med., 1: 142-152, 1995.
48. Haupt, Y., Maya, R., Kazaz, A., and Oren, M. MDM2 promotes the rapid degradation of p53. Nature (Lond.), 387: 296-299, 1997.
49. Kubbutat, M. H. G., Jones, S. N., and Vousden, K. H. Regulation of p53 stability by MDM2. Nature (Lond.), 387: 299-303, 1997.
50. Reifenberger, G., Liu, L., Ichimura, K., Schmidt, E. E., and Collins, V. P. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res., 53: 2736-2739, 1993.
51. Ladanyi, M., Cha, C., Lewis, R., Jhanwar, S. C., Huvos, A. G., and Healey, J. H. MDM2 gene amplification in metastatic osteosarcoma. Cancer Res., 53: 16-18, 1993.
52. Sheikh, M. S., Shao, Z. M., Hussain, A., and Fontana, J. A. The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma. Cancer Res., 53: 3226-3228, 1993.
53. Bueso-Ramos, C. E., Yang, Y., deLeon, E., McCown, P., Stass, S. A., and Albitar, M. The human MDM-2 oncogene is overexpressed in leukemias. Blood, 82: 2617-2623, 1993.
54. Kessis, T. D., Slebos, R. J., Han, S. M., Shah, K., Bosch, X. F., Munoz, N., Hedrick, L., and Cho, K. R. p53 gene mutations and MDM2 amplification are uncommon in primary carcinomas of the uterine cervix. Am. J. Pathol., 143: 1398-1405, 1993.
55. Ikenberg, H., Matthay, K., Schmitt, B., Bauknecht, T., Kiechle-Schwarz, M., Goppinger, A., and Pfleiderer, A. p53 mutation and MDM2 amplification are rare even in human papillomavirus-negative cervical carcinomas. Cancer (Phila.), 76: 57-66, 1995.
56. Durst, M., Croce, C. M., Gissman, L., Schwarz, E., and Huebner, K. Papillomavirus sequences integrate near cellular oncogenes in some cervical carcinomas. Proc. Natl. Acad. Sci. USA, 84: 1070-1074, 1987.
57. Ocadiz, R., Sauceda, R., Cruz, M., Graef, A. M., and Gariglio, P. High correlation between molecular alterations of the c-myc oncogene and carcinoma of the cervix. Cancer Res., 47: 4173-4177, 1987.
58. Riou, G. F. Proto-oncogenes and prognosis in early carcinoma of the uterine cervix. Cancer Surv., 7, 3: 441-456, 1988.
59. Riou, G., Le, M. G., Le Doussal, V., Barrois, M., George, M., and Haie, C. C-myc proto-oncogene expression and prognosis in early carcinoma of the uterine cervix. Lancet, 335: 761-763, 1987.